Ivona Vučić
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ivona Vučić has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Ante Lekić
2 shared publications- Bruno Ban
School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
2 shared publications - Hrvoje Gašparović
Department of Cardiac Surgery, University Hospital Center Zagreb, 10000 Zagreb, Croatia
2 shared publications - Kristina Krzelj
Department of Cardiac Surgery, University Hospital Centre Zagreb, Zagreb, Croatia
2 shared publications - Željko Đurić
Department of cardiac surgery, UHC Zagreb
2 shared publications Alan Horvat
Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, Zagreb, Croatia
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0352417
Early start of hemoadsorption is associated with improved kidney recovery in ICU patients with ischemic/reperfusion cause of rhabdomyolysis
Background: Hemoadsorption is considered currently as an adjunct therapy for the treatment of rhabdomyolysis and acute kidney injury (AKI) although the exact timing is not yet determined. We hypothesised that earlier start of hemoadsorption in patients with ischemia/reperfusion caused rhabdomyolysis and AKI leads to a better clinical improvement and recovery of kidney function. Materials and methods: We conducted a single-center, retrospective cohort study. Treatment was defined as the use of hemoadsorption with CytoSorb® in combination with continuous renal replacement therapy (CRRT) compared to patients who were treated only with CRRT. Patients were divided in early and late initiation of hemoadsorption subgroups by less or more than 12 hours after developing acute kidney injury. Myoglobin and creatine kinase plasma levels were measured shortly before, 12 hours after the start of treatment, and 24, 48, and 72 hours after initiation. The follow-up lasted until the last enrolled patient reached 60 days after first hemoadsorption procedure. Results: Overall, 30 patients were included in the treatment arm and 25 patients in the control group. Significant decrease of myoglobin levels was observed in the hemoadsorption treated group in all time points when compared with the control group. Logistical regression analysis found the association of hemoadsorption use and shorter duration of AKI (OR 3.46) and less acute kidney disease (AKD) (OR 2.85). Earlier start of hemoadsorption was associated with a statistically significant shorter duration of AKI (OR 3.22) and less AKD (OR 3.10). Patients treated early with hemoadsorption survived significantly longer than patients treated late (49.2 vs 15.3 days; p < 0.001). Conclusions: Early start of combined CRRT and hemoadsorption therapy with CytoSorb was safe and associated with improved kidney recovery and survival in patients with ischemic/reperfusion rhabdomyolysis and AKI. Early start of hemoadsorption might prevent renal failure and acute kidney disease and shorten the CRRT dependency in patients who develop AKI.
- 30 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0352417
Open AccessEarly start of hemoadsorption is associated with improved kidney recovery in ICU patients with ischemic/reperfusion cause of rhabdomyolysis
Background: Hemoadsorption is considered currently as an adjunct therapy for the treatment of rhabdomyolysis and acute kidney injury (AKI) although the exact timing is not yet determined. We hypothesised that earlier start of hemoadsorption in patients with ischemia/reperfusion caused rhabdomyolysis and AKI leads to a better clinical improvement and recovery of kidney function. Materials and methods: We conducted a single-center, retrospective cohort study. Treatment was defined as the use of hemoadsorption with CytoSorb® in combination with continuous renal replacement therapy (CRRT) compared to patients who were treated only with CRRT. Patients were divided in early and late initiation of hemoadsorption subgroups by less or more than 12 hours after developing acute kidney injury. Myoglobin and creatine kinase plasma levels were measured shortly before, 12 hours after the start of treatment, and 24, 48, and 72 hours after initiation. The follow-up lasted until the last enrolled patient reached 60 days after first hemoadsorption procedure. Results: Overall, 30 patients were included in the treatment arm and 25 patients in the control group. Significant decrease of myoglobin levels was observed in the hemoadsorption treated group in all time points when compared with the control group. Logistical regression analysis found the association of hemoadsorption use and shorter duration of AKI (OR 3.46) and less acute kidney disease (AKD) (OR 2.85). Earlier start of hemoadsorption was associated with a statistically significant shorter duration of AKI (OR 3.22) and less AKD (OR 3.10). Patients treated early with hemoadsorption survived significantly longer than patients treated late (49.2 vs 15.3 days; p < 0.001). Conclusions: Early start of combined CRRT and hemoadsorption therapy with CytoSorb was safe and associated with improved kidney recovery and survival in patients with ischemic/reperfusion rhabdomyolysis and AKI. Early start of hemoadsorption might prevent renal failure and acute kidney disease and shorten the CRRT dependency in patients who develop AKI.
- 26 December 2025
- Published by Udruga Anestezija in Croatian journal of anaesthesiology and intensive medicine
- Vol. 1 (1) , 31-39
Perioperative management of patients with durable left ventricular assist devices undergoing non-cardiac surgery
Patients receiving durable left ventricular assist devices (lvads) for advanced heart failure present growing perioperative challenges, with nearly one-third undergoing non-cardiac procedures most often in emergent or urgent contexts. this article reviews critical management strategies, emphasizing the importance of multidisciplinary collaboration. device characteristics and operating principles are detailed, focusing on pump types, control parameters, and unique physiological responses in lvad-supported patients. preoperative assessment entails comprehensive echocardiographic evaluation, management of coexisting implantable cardioverter defibrillators (icds), and tailored anticoagulation regimens. warfarin discontinuation and perioperative heparin bridging, consideration of acquired von willebrand syndrome, and preemptive transfusion planning are highlighted to address bleeding risks. infection prevention includes strict sterile technique and timely administration of prophylactic antibiotics targeting skin flora and device-specific pathogens. intraoperatively, vigilant monitoring of device parameters and hemodynamics, invasive arterial blood pressure assessment, and selection of anesthesia approaches are outlined. special attention is given to lvad preload and afterload dependencies, right ventricular support, positioning, and arrhythmia management. acute complications, including suction events, device malfunction, and modified cardiopulmonary resuscitation protocols are addressed, underscoring differences from standard cardiac arrest care. the postoperative phase demands careful icu management, prompt resumption of anticoagulation, and restoration of icd settings. as lvad utilization increases, non-cardiac anesthesiologists are required basic understanding in device physiology, monitoring, anticoagulation, and infection prevention to optimize outcomes for this complex patient population.
- 26 December 2025
- Published by Udruga Anestezija in Croatian journal of anaesthesiology and intensive medicine
- Vol. 1 (1) , 31-39
Perioperative management of patients with durable left ventricular assist devices undergoing non-cardiac surgery
Patients receiving durable left ventricular assist devices (lvads) for advanced heart failure present growing perioperative challenges, with nearly one-third undergoing non-cardiac procedures most often in emergent or urgent contexts. this article reviews critical management strategies, emphasizing the importance of multidisciplinary collaboration. device characteristics and operating principles are detailed, focusing on pump types, control parameters, and unique physiological responses in lvad-supported patients. preoperative assessment entails comprehensive echocardiographic evaluation, management of coexisting implantable cardioverter defibrillators (icds), and tailored anticoagulation regimens. warfarin discontinuation and perioperative heparin bridging, consideration of acquired von willebrand syndrome, and preemptive transfusion planning are highlighted to address bleeding risks. infection prevention includes strict sterile technique and timely administration of prophylactic antibiotics targeting skin flora and device-specific pathogens. intraoperatively, vigilant monitoring of device parameters and hemodynamics, invasive arterial blood pressure assessment, and selection of anesthesia approaches are outlined. special attention is given to lvad preload and afterload dependencies, right ventricular support, positioning, and arrhythmia management. acute complications, including suction events, device malfunction, and modified cardiopulmonary resuscitation protocols are addressed, underscoring differences from standard cardiac arrest care. the postoperative phase demands careful icu management, prompt resumption of anticoagulation, and restoration of icd settings. as lvad utilization increases, non-cardiac anesthesiologists are required basic understanding in device physiology, monitoring, anticoagulation, and infection prevention to optimize outcomes for this complex patient population.
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 122
Complex mitral valve re-repair utilizing homograft mitral valve tissues
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 122
Complex mitral valve re-repair utilizing homograft mitral valve tissues
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 123
A case report of combined tricuspid valve and pulmonary valve repair
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 123
A case report of combined tricuspid valve and pulmonary valve repair